Russell Investments Group Ltd. Has $3.41 Million Position in Alphatec Holdings, Inc. $ATEC

Key Points

• Russell Investments Group Ltd. increased its stake in Alphatec Holdings, Inc. by 68.3% during the 1st quarter, holding approximately 336,463 shares valued at $3.41 million.
• Several institutional investors, including Comerica Bank and Quarry LP, also boosted their stakes in Alphatec, indicating strong interest in the company's stock.
• Alphatec reported earnings of $0.02 per share for the last quarter, exceeding analysts' expectations, with revenues up 27.5% year-over-year, totaling $185.54 million.

Russell Investments Group Ltd. lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 68.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 336,463 shares of the medical technology company's stock after purchasing an additional 136,577 shares during the period. Russell Investments Group Ltd. owned about 0.23% of Alphatec worth $3,412,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in ATEC. Nuveen LLC acquired a new stake in shares of Alphatec in the 1st quarter worth approximately $135,874,000. Royal Bank of Canada boosted its position in Alphatec by 171.2% during the fourth quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock valued at $29,240,000 after purchasing an additional 2,010,806 shares during the last quarter. Nuveen Asset Management LLC increased its stake in shares of Alphatec by 78.4% during the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after purchasing an additional 1,136,330 shares during the last quarter. Motley Fool Wealth Management LLC bought a new position in Alphatec during the first quarter valued at about $9,070,000. Finally, Western Standard LLC bought a new position in Alphatec in the 4th quarter worth $6,668,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Performance

ATEC stock traded down $0.22 during mid-day trading on Thursday, hitting $15.97. 1,184,160 shares of the company were exchanged, compared to its average volume of 2,058,977. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $16.47. The stock has a market capitalization of $2.36 billion, a PE ratio of -14.14 and a beta of 1.05. The business has a 50 day simple moving average of $12.68 and a 200-day simple moving average of $11.66. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same period last year, the firm posted ($0.29) EPS. The firm's revenue for the quarter was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Alphatec

In other Alphatec news, EVP Craig E. Hunsaker sold 186,122 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total transaction of $2,296,745.48. Following the completion of the transaction, the executive vice president directly owned 1,463,896 shares in the company, valued at $18,064,476.64. The trade was a 11.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Scott Lish sold 36,081 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.53, for a total value of $452,094.93. Following the sale, the chief operating officer owned 708,855 shares of the company's stock, valued at $8,881,953.15. The trade was a 4.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 410,247 shares of company stock valued at $5,376,804 in the last ninety days. 20.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a report on Monday, June 16th. Wall Street Zen upgraded shares of Alphatec from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.